SCIENTIFIC-PRACTICAL JOURNAL

| укр | рус |

 

 


No6(5) 2022

Back to the issue


DOI 10.37219/2528-8253-2022-6-66

Deyeva JuV
Evaluation of the clinical efficacy of anti-inflammatory therapy with topical biclotymol-based products   
Dieieva Julia V.
MD, PhD, professor
Head of the department of Otorhinolaryngology
Bogomolets National Medical University, Kiev
E-mail: deyeva@bigmir.net
ORCID ID: 0000-0003-0552-1254
https://www.scopus.com/authid/detail.uri?authorId=55359076200

Abstract

Topicality: Acute pharyngeal diseases are one of the most common reasons for patients to visit a doctor.
According to the UK, approximately 50% of these diseases account for the appointment of antibacterial agents.
Most of these prescriptions are not rational, but doctors use them for several reasons - unreal expectations of treatment, patient pressure/insistence on conducting the desired tests or treatment, the doctor's desire to maintain a better doctor-patient relationship, limited consultation time, diagnostic uncertainty, incorrect collection of historical data and others. Despite these reasons, patients with acute pharyngitis and tonsillitis who seek antibiotic therapy want to reduce their symptoms. Therefore, the search for agents that will significantly improve patients' quality of life during acute pharyngeal diseases is crit ical.
Aim: To review the literature on the therapeutic efficacy of topical biclotymol-based products for treating acute pharyngeal diseases.
Results and discussion: Most cases of acute pharyngitis should be treated with over-the-counter medicines that are primarily intended to control the symptoms of the disease and improve the patient's quality of life. Biclotymol, enoxolone and lysozyme are novel substances that, at the same time, are safe for resolving pain in viral or bacterial pharyngit is. Biclotymol can be used as monotherapy and in combination with other agents. In the analysed data, biclotymol showed its therapeutic efficacy and safety. Therefore, it is safe to recommend biclotymolbased products for use in acute viral and bacterial pharyngitis or tonsillitis both as monocomponent medicine and fixed-dose combination.

Keywords

acute pharyngitis, acute tonsillitis, treatment, Biclotimol.


Reference

  1. Chorna VV, Khliestova SS, Gumeniuk NI, Makhniuk VM, Sydorchuk TM. [Morbidity indicators and dissemination and modern attitudes on disease prevention]. Reports of the Vinnytsia National Medical University. 2020;24(1):158-64. doi:10.31393/reports-vnmedical-2020-24(1)-31. [Article in Ukrainian].
  2. Worrall GJ. Acute sore throat. Can Fam Physician. 2007;53(11):1961-2.
  3. Bennett J, Dolin R, Blaser M, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Elsevier; 2015. Bryant AE, Stevens DL. Streptococcus pyogenes; p. 2285-99.
  4. Dolk FCK, Pouwels KB, Smith DRM, Robotham JV, Smieszek T. Antibiotics in primary care in England: which antibiotics are prescribed and for which conditions? J Antimicrob Chemother. 2018; 73(suppl_2):ii2-ii10. doi: 10.1093/jac/dkx504.
  5. Little P, Dorward M, Warner G, Stephens K, Senior J, Moore M. Importance of patient pressure and perceived pressure and perceived medical need for investigations, referral, and prescribing in primary care: nested observational study. BMJ. 2004;328 (7437):444. doi: 10.1136/bmj.38013.644086.7C.
  6. van Driel ML, De Sutter A, Deveugele M, Peersman W, But ler CC, De Meyere M, et al. Are sore throat patients who hope for antibiotics actually asking for pain relief? Ann Fam Med. 2006;4(6): 494-9. doi: 10.1370/afm.609.
  7. van der Velden AW, Bell J, Sessa A, Duerden M, Altiner A. Sore throat: effective communication delivers improved diagnosis, enhanced self-care and more rational use of antibiotics. Int J Clin Pract Suppl. 2013;67(180):10-6. doi:10.1111/ijcp.12336.
  8. Masheyko AM. [Analysis of the incidence of acute pharyngitis and tonsillitis and their poststreptococcal complications in children in Ukraine]. Social pharmacy in health care. 2017; 3(1):14-22. doi: 10.24959/sphhcj.17.73. [Article in Ukrainian].
  9. Shafranskyi VV. [Annual report on the state of health of the population, the sanitary-epidemic situation and the results of the health care system of Ukraine]. State institution "Ukrainian institute of strategic research of the Ministry of health of
    Ukraine"; 2016. 452 p. [In Ukrainian].
  10. Spinks A, Glasziou PP, Del Mar CB. Antibiotics for sore throat. Cochrane Database Syst Rev. 2013; 2013(11):CD000023. doi: 10.1002/14651858.CD000023.pub4.
  11. Carapetis J, Bowen A, May P. The inequitable burden of group A streptococcal diseases in Indigenous Australians: we need to fill evidence gaps and make clinical advances to reduce these diseases of disadvantage (Report). Med J Aust. 2016;205(5):201-3. doi: 10.5694/mja16.00400.
  12. Oliver JR, Pierse N, Stefanogiannis N, Jackson C, Baker MG. Acute rheumatic fever and exposure to poor housing conditions in New Zealand: A descriptive study. J Paediatr Child Health. 2017 Apr;53(4):358-364. doi: 10.1111/jpc.13421.
  13. ESCMID Sore Throat Guideline Group, Pelucchi C, Grigoryan L, Galeone C, Esposito S, Huovinen P, Little P, Verheij T. Guideline for the management of acute sore throat. Clin Microbiol Infect. 2012;18 Suppl 1:1-28. doi: 10.1111/j.1469-
    0691.2012. 03766.x.
  14. SchammÒ‘e B, Couvrat N, Malpeli P, Dudognon E, Delbreilh L, Dupray V, Dargent, E, Coquerel G. Transformation of an active pharmaceutical ingredient upon high energy milling: A process-induced disorder in Biclotymol. Int J Pharm. 2016;499(1-2):67-73. doi: 10.1016/j.ijpharm.2015.12.032.
  15. Deeva YV. [The results of complex application drugsHexalyse and Hexaspray in the treatment of inflammatory diseases of the throat] Family Medicine. 2015;58(2):149-52. [Article in Ukrainian].
  16. Chevalier E. [Etude en double aveugle contre placebo de l’activitи therapeutique de Hexaspray dans les angines et pharyngites aigues]. Gazette Medicale 1987;94:73-5. [Article in French].
  17. Karpova E, Giacomelli L, Tumietto F. Role of biclotymol-based products in the treatment of infectious sore throat. Eur Rev Med Pharmacol Sci. 2017;21(16):3736-3743.
  18. Fuji HY, Tian J, Luka C. Effect of glycyrrhetinic acid on influenza virus and pathogenic bacteria. Trends in Pharmacological Sciences. 1986;(1): 238-41.
  19. Lin JC. Mechanism of action of glycyrrhizic acid in inhibition of EpsteinBarr virus replication in vitro. Antiviral Res. 2003;59(1):41-7. doi: 10.1016/s0166-3542(03)00030-5.
  20. Callewaert L, Michiels CW. Lysozymes in the animal kingdom. J Biosci. 2010;35(1):127-60. doi: 10.1007/s12038-010-0015-5.
  21. Cartel F, Cartei G, Ceschia V, Pacor S, Sava G. Recovery of lymphocyte CD4+:CD8+ratio in patients treated with lysozyme. Drug Investig. 1992; (4):51-7. https://doi.org/10.1007/BF03258379.
  22. Gallo D, Cocchietto M, Masat E, Agostinis C, Harei E, Veronesi P, et al. Human recombinant lysozyme downregulates advanced glycation endproduct-induced interleukin-6 production and release in an in-vitro model of human proximal tubular epithelial cells. Exp Biol Med (May-wood). 2014;239(3):337-46. doi: 10.1177/1535370213518281.
  23. Bergamo A, Gerdol M, Pallavicini A, Greco S, Schepens I, Hamelin R, et al. Lysozyme-induced transcriptional regulation of TNF-αpathway genes in cells of the monocyte lineage. Int J Mol Sci. 2019;20(21):5502. doi: 10.3390/ijms20215502.
  24. Tagashira A, Nishi K, Matsumoto S, Sugahara T. Anti-inflammatory effect of lysozyme from hen egg white on a mouse peritoneal macrophages. Cytotechnology. 2018;70(3):929-38. doi: 10.1007/s10616-017-0184-2.
  25. Del Mar CB, Glasziou PP, Spinks AB. Ant ibiot ics for sore throat. Cochrane Database Syst Rev. 2006; (4):CD000023. doi:10.1002/14651858.CD000023.pub3.
  26. Oxford JS, Leuwer M. Acute sore throat revisted: clinical and experimental evidence for efficacy of over-the-counter AMC/DCBA throat lozenges. Int J Clin Pract. 2011;65(5):524-30. doi: 10.1111/j.1742-1241.2011.02644.x.
 

© 2019, Public Organization «Ukrainian Scientific Medical Society of Otorhinolaryngologists»